Technical Outlook And Game Plan For Mersana Therapeutics Inc (NASDAQ: MRSN)

Mersana Therapeutics Inc (MRSN) concluded trading on Thursday at a closing price of $4.23, with 2.7 million shares of worth about $11.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 252.50% during that period and on Thursday the price saw a gain of about 17.83%. Currently the company’s common shares owned by public are about 105.14M shares, out of which, 94.33M shares are available for trading.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 174,616 shares in 16 of the transactions. In 3 selling transactions, insiders dumped 7,764 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stock saw a price change of 25.15% in past 5 days and over the past one month there was a price change of 30.96%. Year-to-date (YTD), MRSN shares are showing a performance of 82.33% which decreased to -36.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.80 but also hit the highest price of $9.62 during that period. The average intraday trading volume for Mersana Therapeutics Inc shares is 1.87 million. The stock is currently trading 33.97% above its 20-day simple moving average (SMA20), while that difference is up 68.11% for SMA50 and it goes to 40.37% higher than SMA200.

Mersana Therapeutics Inc (NASDAQ: MRSN) currently have 105.14M outstanding shares and institutions hold larger chunk of about 74.39% of that.

The stock has a current market capitalization of $510.05M and its 3Y-monthly beta is at 1.36. It has posted earnings per share of -$1.78 in the same period. It has Quick Ratio of 3.68 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRSN, volatility over the week remained 11.33% while standing at 10.60% over the month.

Analysts are in expectations that Mersana Therapeutics Inc (MRSN) stock would likely to be making an EPS of $Mersana Therapeutics, Inc. in the current quarter, while forecast for next quarter EPS is $4.23 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $NeuroSense Therapeutics Ltd. which is $Marinus Pharmaceuticals, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Marin Software Incorporated in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 30.40% while it is estimated to increase by 51.31% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on December 04, 2023 offering a Buy rating for the stock and assigned a target price range of between $1 and $5 to it.

Most Popular

Related Posts